Alimera Sciences Stock
Your prediction
Pros and Cons of Alimera Sciences in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alimera Sciences vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alimera Sciences | - | - | - | - | - | - | - |
| Rockwell Medical Inc. | 0.000% | -5.590% | -7.090% | -14.655% | 12.343% | -57.918% | -91.154% |
| Pacira Pharmaceuticals | -0.990% | -2.475% | 0.510% | -6.190% | -8.796% | -48.158% | -62.476% |
| Twist Bioscience Corp | 1.870% | 8.822% | 22.035% | 41.452% | 71.418% | 275.314% | -57.715% |
Comments
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) is now covered by analysts at Maxim Group. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat
Alimera Sciences, Inc. (NASDAQ: ALIM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Show more
Ratings data for ALIM provided by MarketBeat